Investigating the effect of resveratrol on polycystic ovary syndrome

Investigating the effect of resveratrol administration on the expression of factors involved in mitochondrial function and biogenesis in granulosa cells of patients with PCOS who are candidates for ART: a three-blind randomized controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221106056417N1

Enrollment

Registered

2023-02-09

Start date

2023-04-21

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Polycystic ovary syndrome

Interventions

Intervention group: use of resveratrol. In this group of patients, for 60 days until puncture, they take two capsules of 800 mg of resveratrol daily, twice in the morning and in the evening. Their rou

Eligibility

Sex/Gender

Female

Age

18 Years to 35 Years

Inclusion criteria

Inclusion criteria: Diagnosis of Polycystic ovary syndrome (PCOS) based on Rotterdam criteria Polycystic ovary syndrome (PCOS) patients who are candidates for ART

Exclusion criteria

Exclusion criteria: Pregnancy Adrenal hyperplasia Androgen-secreting tumors Hyperprolactinemia Thyroid dysfunction Diabetes or impaired glucose tolerance

Design outcomes

Primary

Measure	Time frame
Examining PGC1 alpha, Nrf1, TFAM, UCP2 genes expression. Timepoint: Sixty days after taking the medicine. Method of measurement: real time PCR.;Analysis of SIRT1, PGC1 alpha, UCP2 protein expression. Timepoint: Sixty days after taking the medicine. Method of measurement: Western Blot.;Analysis mtDNA. Timepoint: Sixty days after taking the medicine. Method of measurement: the quantitative real-time (q)PCR reactions.;Total antioxidant capacity (TAC). Timepoint: 60 days after the start of the intervention, check the follicular fluid and granulosa cells. Method of measurement: ELIZA.;Total oxidant statues (TOS). Timepoint: 60 days after the start of the intervention, check on follicular fluid and granulosa cells. Method of measurement: ELIZA.;Examination of antioxidant genes. Timepoint: Sixty days after taking the medicine. Method of measurement: real time PCR.;Examining the content of intracellular ATP. Timepoint: Sixty days after taking the medicine. Method of measurement: ELIZA.;Examination of the oxidative stress index (OSI) (OSI). Timepoint: Sixty days after taking the medicine. Method of measurement: determined by dividing TOS by TAC.;Investigating the antioxidant markers of follicular fluid. Timepoint: Sixty days after taking the medicine. Method of measurement: ELIZA.	—

Measure

Time frame

Examining PGC1 alpha, Nrf1, TFAM, UCP2 genes expression. Timepoint: Sixty days after taking the medicine. Method of measurement: real time PCR.;Analysis of SIRT1, PGC1 alpha, UCP2 protein expression. Timepoint: Sixty days after taking the medicine. Method of measurement: Western Blot.;Analysis mtDNA. Timepoint: Sixty days after taking the medicine. Method of measurement: the quantitative real-time (q)PCR reactions.;Total antioxidant capacity (TAC). Timepoint: 60 days after the start of the intervention, check the follicular fluid and granulosa cells. Method of measurement: ELIZA.;Total oxidant statues (TOS). Timepoint: 60 days after the start of the intervention, check on follicular fluid and granulosa cells. Method of measurement: ELIZA.;Examination of antioxidant genes. Timepoint: Sixty days after taking the medicine. Method of measurement: real time PCR.;Examining the content of intracellular ATP. Timepoint: Sixty days after taking the medicine. Method of measurement: ELIZA.;Examination of the oxidative stress index (OSI) (OSI). Timepoint: Sixty days after taking the medicine. Method of measurement: determined by dividing TOS by TAC.;Investigating the antioxidant markers of follicular fluid. Timepoint: Sixty days after taking the medicine. Method of measurement: ELIZA.

—

Secondary

Measure	Time frame
The number and quality of oocytes. Timepoint: 60 days after the start of the intervention. Method of measurement: Counting, optical microscopy.;Number and quality of embryos. Timepoint: 60 days after the start of the intervention. Method of measurement: Counting, optical microscopy.;Chemical pregnancy. Timepoint: 16 days after embryo transfer. Method of measurement: hCG blood tests.;Clinical pregnancy. Timepoint: around 7 weeks of gestation. Method of measurement: the presence of a gestational sac, fetal heartbeat observed at ultrasound scan.	—

Measure

Time frame

The number and quality of oocytes. Timepoint: 60 days after the start of the intervention. Method of measurement: Counting, optical microscopy.;Number and quality of embryos. Timepoint: 60 days after the start of the intervention. Method of measurement: Counting, optical microscopy.;Chemical pregnancy. Timepoint: 16 days after embryo transfer. Method of measurement: hCG blood tests.;Clinical pregnancy. Timepoint: around 7 weeks of gestation. Method of measurement: the presence of a gestational sac, fetal heartbeat observed at ultrasound scan.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTayebe Rastgar

Tehran University of Medical Sciences

trastegar@sina.tums.ac.ir+98 21 8889 6696

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 6, 2026